Melanotan II: Tanning Peptide Research & Risks

For decades, the cosmetic appeal of a golden tan has driven people to bake under the sun or lie in tanning beds — practices known to increase skin cancer risk. In the 1980s, researchers at the University of Arizona thought they'd found a solution: a synthetic peptide that could stimulate melanin production without UV exposure. What emerged was Melanotan II, a compound that does indeed darken skin, but also triggers a cascade of unexpected effects throughout the body, from spontaneous erections to kidney failure.

Today, Melanotan II occupies a peculiar space in the peptide world. It's not approved by any regulatory authority. It's illegal to sell for human use in most countries. Yet it remains widely available through internet vendors and gym networks, marketed as a quick path to a year-round tan. The promise is compelling, but the risks are substantial and, in some cases, severe. This article examines what Melanotan II is, how it works, what the research shows, and why health authorities worldwide warn against its use.

Table of Contents

• Quick Facts
• What Is Melanotan II?
• Development History
• Mechanism of Action
  • The Melanocortin System
  • Why Non-Selectivity Matters
• Research Evidence
  • Tanning Studies
  • Sexual Function Studies
  • Metabolic Effects
• Risks and Safety Concerns
  • Mole Changes and Melanoma
  • Kidney Damage
  • Cardiovascular Effects
  • Sexual Side Effects
  • Common Side Effects
• Legal Status
• Melanotan II vs Melanotan I
• From Melanotan II to PT-141
• Frequently Asked Questions
• The Bottom Line
• References

Quick Facts

Attribute	Details
Full Name	Melanotan II (MT-II)
Type	Synthetic cyclic melanocortin receptor agonist
Structure	Cyclic heptapeptide (7 amino acids with lactam ring)
Molecular Formula	C50H69N15O9
Receptors	MC1R, MC3R, MC4R, MC5R (non-selective)
Developer	University of Arizona (1980s)
Key Researchers	M.E. Hadley, V.J. Hruby
Route	Subcutaneous injection, intranasal (nasal sprays)
FDA Status	Not approved
Legal Status	Illegal to sell for human use in US, UK, Australia, and most countries
Research Use	Available to licensed researchers only

What Is Melanotan II?

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide hormone that regulates skin pigmentation. Unlike the body's own α-MSH, which has a half-life of only about 10 minutes and breaks down quickly, Melanotan II was engineered for stability and prolonged activity.

The peptide is a cyclic heptapeptide — a seven-amino-acid sequence formed into a ring structure through a lactam bond. This cyclic configuration makes it more resistant to degradation than its linear cousin, Melanotan I, and gives it enhanced binding affinity to multiple melanocortin receptors throughout the body.

Originally developed as a potential sunless tanning agent to reduce skin cancer risk, Melanotan II quickly revealed effects far beyond simple pigmentation. During early testing, researchers discovered it caused sexual arousal and spontaneous erections in male subjects — an effect that ultimately led to the development of PT-141 (bremelanotide), an FDA-approved treatment for sexual dysfunction.

Development History

The story of Melanotan II begins at the University of Arizona in the 1980s, where researchers M.E. Hadley and V.J. Hruby were investigating ways to prevent skin cancer. Their hypothesis was straightforward: if they could stimulate melanin production without UV exposure, people could develop a protective tan that would shield them from solar radiation damage.

The team started with α-MSH, the body's natural tanning hormone. But when they tried to administer it directly, they hit a fundamental problem: α-MSH degrades within minutes in the bloodstream, making it impractical as a therapeutic agent. The solution was to create synthetic analogs with longer half-lives. This led to the development of two compounds: Melanotan I, a linear 13-amino-acid peptide, and Melanotan II, a shorter cyclic variant.

According to reports from the University of Arizona, one of the early breakthroughs came from self-experimentation. Researcher Mac Hadley accidentally injected himself with twice the intended dose of Melanotan II and experienced an eight-hour erection along with nausea and vomiting. This unexpected effect signaled that the peptide was doing far more than just tanning skin — it was activating multiple receptor systems throughout the body.

Melanotan I was licensed to an Australian company for development as a photoprotective agent. Melanotan II, meanwhile, was licensed to Palatin Technologies, which recognized its potential as a treatment for sexual dysfunction. Palatin eventually ceased development of Melanotan II in favor of a related compound, bremelanotide (PT-141), which received FDA approval in 2019 for hypoactive sexual desire disorder in women.

Neither Melanotan I nor Melanotan II ever received regulatory approval as tanning agents. Their development as pharmaceutical drugs was halted years ago due to safety concerns. Yet both compounds — particularly Melanotan II — continue to circulate through unregulated online markets.

Mechanism of Action

The Melanocortin System

To understand how Melanotan II works, you need to understand the melanocortin system — a network of receptors and hormones that regulate everything from skin color to appetite, sexual function, and inflammation.

At the center of this system is α-MSH, a small peptide derived from a larger precursor protein called proopiomelanocortin (POMC). α-MSH binds to five different melanocortin receptors (MC1R through MC5R), each of which is expressed in different tissues and controls different physiological processes:

• MC1R (Melanocortin-1 Receptor): Found primarily in melanocytes (the pigment-producing cells in skin). Activation drives melanin synthesis, resulting in skin darkening.
• MC3R (Melanocortin-3 Receptor): Expressed in the brain and involved in energy balance, inflammation, and possibly sexual function.
• MC4R (Melanocortin-4 Receptor): Located in the hypothalamus and other brain regions. Regulates appetite, energy expenditure, and sexual arousal. Activation suppresses appetite and can trigger erectile responses.
• MC5R (Melanocortin-5 Receptor): Found in sebaceous glands, immune cells, and other tissues. Involved in sebum production and immune modulation.

Natural α-MSH has some selectivity for certain receptors, but it still activates all five to varying degrees. Melanotan II, as described in research on melanocortin mechanisms, is a non-selective agonist — it binds to and activates MC1R, MC3R, MC4R, and MC5R with relatively similar potency.

This is both the source of its tanning effects and the root of its problems.

Why Non-Selectivity Matters

When you take Melanotan II, you're not just activating one pathway. You're flipping switches throughout your body:

• Skin (MC1R): Melanocytes ramp up melanin production, darkening your skin.
• Brain (MC4R): Appetite centers in the hypothalamus are suppressed, reducing hunger. Sexual arousal pathways are triggered, leading to increased libido and, in males, spontaneous erections.
• Metabolic tissues (MC3R, MC4R): Energy expenditure may increase, potentially contributing to fat loss.
• Other tissues (MC5R): Effects on sebaceous glands, immune cells, and possibly other systems.

In drug development, selectivity is usually desirable. You want a compound that hits one target cleanly without affecting others. Melanotan II does the opposite. Its lack of selectivity means that while you might get the tan you're looking for, you're also activating systems you may not want to engage — including pathways linked to serious adverse events.

The cyclic structure of Melanotan II contributes to this problem. According to studies published on melanocortin receptor pharmacology, the lactam ring increases binding affinity to MC1R and MC4R compared to linear peptides like Melanotan I. This makes Melanotan II more potent — you need less of it to get an effect — but it also amplifies the unintended consequences of hitting multiple receptors at once.

Research Evidence

Tanning Studies

The first human study of Melanotan II's tanning effects was published in 1996 by researchers at the University of Arizona (Dorr et al., Life Sci. 1996). The trial was a single-blind, placebo-controlled study involving three healthy male volunteers. Subjects received subcutaneous injections of Melanotan II at a starting dose of 0.01 mg/kg daily (Monday through Friday) for two consecutive weeks.

Results showed increased pigmentation in the face, upper body, and buttocks after just five low-dose injections. The tanning occurred without UV exposure, confirming that Melanotan II can stimulate melanin production independently of solar radiation. However, side effects were notable even at these low doses: subjects experienced nausea, yawning, and stretching episodes.

A later dose-finding study found that at 0.025 mg/kg, 12.9% of subjects had severe nausea. At 0.03 mg/kg, subjects experienced Grade II somnolence and fatigue. These early trials revealed a narrow therapeutic window — the dose required for tanning was close to the dose that caused intolerable side effects.

According to a comprehensive review published in Clinical Toxicology, eighteen clinical trials and twenty-one clinical case presentations have been published on melanotan compounds, but none have led to regulatory approval for tanning indications. The development pathway was abandoned due to safety concerns that outweighed any potential benefits.

Sexual Function Studies

Melanotan II's most documented "off-target" effect is on sexual function. In a 2000 study published in the International Journal of Impotence Research (Wessells et al.), researchers administered Melanotan II to 20 men with psychogenic and organic erectile dysfunction using a double-blind, placebo-controlled crossover design.

Results were striking:

• Penile erections occurred in 17 of 20 men in the absence of sexual stimulation.
• Increased sexual desire was reported after 68% of Melanotan II doses, compared to 19% of placebo doses.
• Erections typically began 1–5 hours after administration and were associated with yawning and stretching.

These effects are mediated primarily through MC4R activation in the hypothalamus and spinal cord. The discovery led Palatin Technologies to pursue Melanotan II as a treatment for erectile dysfunction and later to develop PT-141 (bremelanotide), a modified analog with improved side effect profile that received FDA approval for female sexual dysfunction in 2019.

While the erectile effects might sound desirable, they're often unwanted and poorly timed. Case reports describe priapism (prolonged, painful erection) requiring emergency intervention. One published case in a urology journal documented a man who developed priapism lasting several hours after using Melanotan II purchased online, requiring medical treatment to resolve.

Metabolic Effects

Melanotan II's effects on appetite and metabolism have been documented in both animal and human studies. MC4R activation in the hypothalamus suppresses food intake and increases energy expenditure. A study on melanocortin system activation found that chronic administration of Melanotan II reduced body mass in animal models without the necessity of long-term caloric restriction.

In human trials, decreased appetite was one of the most commonly reported effects. While some users view this as a benefit, it's actually evidence of central nervous system activation — the peptide is altering brain circuits that regulate hunger and satiety.

The metabolic effects are not entirely understood. Some research suggests Melanotan II may improve glucose handling and lipid metabolism through MC4R-mediated pathways, but these findings come from animal studies and haven't been validated in controlled human trials. Given the lack of regulatory oversight and quality control in illicit Melanotan II products, any metabolic "benefits" are speculative at best and overshadowed by documented risks.

Risks and Safety Concerns

Mole Changes and Melanoma

One of the most concerning risks associated with Melanotan II is its effect on existing moles and its potential link to melanoma. Multiple case reports and clinical observations document changes in melanocytic lesions following Melanotan II use.

Mole Darkening and Proliferation: Melanotan II can cause generalized skin tanning, darkening of multiple moles, and enlargement of suspicious lesions within weeks of use. According to Australian health authorities, the drug can cause a sudden increase in moles and freckles, and in some people — especially those with light skin — changes in the shape of moles and new moles have all occurred.

Dysplastic Nevi: A case report published in Actas Dermo-Sifiliográficas described eruptive dysplastic nevi (atypical moles) in a patient following melanotan use. Another report documented a 16-year-old girl who developed multiple dark melanocytic nevi and an enlarging nevus after self-injecting Melanotan II and using tanning beds. Histopathology revealed dysplastic compound nevus, a precursor to melanoma.

Patients with preexisting risk factors — fair skin (phototype I or II), multiple moles, personal or family history of melanoma — appear particularly vulnerable. In these individuals, Melanotan II may accelerate the transformation of benign nevi into dysplastic lesions.

Melanoma Risk: Direct causation between Melanotan II and melanoma has not been definitively established, but the theoretical risk is plausible. Stimulating melanocyte proliferation in individuals already predisposed to skin cancer could jumpstart progression to melanoma. A 2014 case report in Dermatology documented melanoma associated with Melanotan II use, and another case described melanoma in situ in a patient using Melanotan II.

A 2021 review concluded that "the increased risk of melanoma in Melanotan users, who use it for tanning and exhibit sun-seeking behavior, can probably be explained by more UV exposure." However, the peptide's direct effects on melanocyte behavior remain poorly understood and unstudied in long-term trials.

As researchers have stated in published literature: "As long as the question of carcinogenesis has not been adequately addressed, the harmlessness of melanotan should not be promoted."

Monitoring Difficulty: One insidious aspect of Melanotan II's effects on moles is that it makes skin self-examination harder. When all your moles darken at once, distinguishing normal pigmentation from abnormal changes becomes nearly impossible. This masks warning signs of skin cancer — exactly the opposite of what a photoprotective agent should do.

Kidney Damage

Multiple case reports document serious kidney injury following Melanotan II use. The most common presentations are rhabdomyolysis (muscle breakdown) and renal infarction (blocked blood flow to the kidneys).

Rhabdomyolysis and Acute Kidney Injury: A 2012 case published in Clinical Toxicology described a 39-year-old man who injected 6 mg of Melanotan II purchased online — six times the recommended starting dose. Within two hours, he presented to the emergency department with:

• Diffuse body aches
• Blood pressure of 151/85 mmHg
• Heart rate of 130–146 bpm
• Muscle tremors
• Elevated creatine phosphokinase (CPK) levels indicating muscle breakdown

The patient developed rhabdomyolysis and renal dysfunction requiring ICU admission and aggressive fluid resuscitation with sodium bicarbonate. His CPK peaked, then gradually decreased over three days as kidney function improved.

Renal Infarction: A 2020 case report in BMC Nephrology documented renal infarction in a previously healthy 45-year-old man who used Melanotan II during a vacation in Southern Europe. He presented with right-sided abdominal pain, vomiting, and increased urination frequency. Imaging revealed renal infarction, and the patient had no other identifiable risk factors.

The mechanism of kidney injury is not fully understood. Possibilities include:

• Thrombotic effects: Melanotan II may promote blood clot formation, blocking renal blood vessels.
• Direct toxicity: The peptide or contaminants in illicitly manufactured products may damage kidney tissue.
• Sympathomimetic effects: Elevated heart rate and blood pressure could contribute to vascular injury.

Cardiovascular Effects

Melanotan II affects the cardiovascular system through multiple mechanisms. While some animal studies suggest potential anti-inflammatory and cardioprotective effects in atherosclerosis models, human case reports tell a different story.

Blood Pressure: The effects on blood pressure appear dose-dependent and variable. Some studies in anesthetized animals showed slight reductions in systemic blood pressure at certain doses, but case reports document blood pressure elevations in humans. In the rhabdomyolysis case cited above, a previously normotensive patient had blood pressure recorded at 165/95 mmHg after using Melanotan II.

Tachycardia: Increased heart rate (tachycardia) is commonly reported. The same case documented heart rates of 130–146 bpm, consistent with sympathetic nervous system activation.

Flushing: Facial flushing is one of the most frequent side effects, resulting from vasodilation. While not dangerous in itself, it reflects systemic vascular effects.

These cardiovascular effects are particularly concerning for individuals with preexisting heart conditions or hypertension. Without medical supervision or FDA-approved dosing guidelines, users have no way to predict or manage these responses.

Sexual Side Effects

While some users seek out Melanotan II specifically for its sexual effects, these effects are often problematic.

Spontaneous Erections and Priapism: As documented in clinical trials, 17 of 20 men experienced erections without sexual stimulation. This might sound beneficial in the context of erectile dysfunction, but in healthy men using the peptide for tanning, it's an unwanted side effect.

Priapism — prolonged, painful erection lasting hours — has been reported in multiple cases. Priapism is a medical emergency; if not treated promptly, it can result in permanent erectile dysfunction due to tissue damage. Published case reports describe men requiring emergency medical intervention after using Melanotan II.

Effects in Women: Melanotan II has also been shown to increase sexual desire in women. While this led to the development of bremelanotide (PT-141) for hypoactive sexual desire disorder, the uncontrolled sexual arousal effects in women using illicit Melanotan II for tanning are typically unwanted and distressing.

Common Side Effects

Beyond the serious risks, Melanotan II commonly causes a range of less severe but unpleasant side effects:

• Nausea: One of the most frequent complaints. In early trials, 12.9% of subjects at 0.025 mg/kg had severe nausea.
• Yawning and stretching: Occur in most users, often preceding erectile effects. Thought to be mediated through central melanocortin pathways.
• Flushing: Facial redness and warmth.
• Fatigue and somnolence: Drowsiness and lack of energy.
• Decreased appetite: Weight loss may occur.
• Injection site reactions: Pain, redness, or swelling at injection sites.

According to a qualitative study of online discussion forums, users frequently report these effects and attempt to mitigate them through dose adjustments, antiemetics, or timing changes — all without medical guidance.

Legal Status

Melanotan II is not approved by any major regulatory authority for human use.

United States: The FDA has not approved Melanotan I or Melanotan II for any medical indication. According to FDA regulations, their sale and marketing for human use are illegal. The compounds can be legally synthesized and sold to qualified researchers for in-vitro or non-human experimental purposes only.

Despite being illegal, Melanotan II is still widely sold on the internet, often marketed as "research peptides" with disclaimers stating "not for human consumption." These disclaimers are legally meaningless — the products are clearly intended for human use, and their sale violates federal law.

United Kingdom: It is illegal to sell Melanotan II in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued warnings about the risks and illegality of these products.

Australia: The Therapeutic Goods Administration (TGA) explicitly warns against Melanotan II use and has banned its sale and advertisement. According to TGA statements, the development of Melanotan II as a potential medicine was halted years ago due to safety reasons.

Ireland: The Health Products Regulatory Authority (HPRA) issued a reminder of serious health risks and confirmed that Melanotan II is not authorized to treat any condition.

European Union, Canada, and elsewhere: Most countries follow similar regulatory stances. Melanotan II is not approved, and its sale for human use is prohibited.

Melanotan II vs Melanotan I

Melanotan I and Melanotan II are both synthetic α-MSH analogs, but they differ in structure, receptor selectivity, potency, and side effect profiles.

Feature	Melanotan I (Afamelanotide)	Melanotan II
Structure	Linear 13-amino-acid peptide	Cyclic 7-amino-acid peptide with lactam ring
Receptor Selectivity	More selective for MC1R	Non-selective: binds MC1R, MC3R, MC4R, MC5R
Potency	Less potent; requires higher doses	More potent; effective at lower doses
Tanning Effect	Effective but slower	Rapid tanning at lower cumulative doses
Sexual Effects	Minimal to none	Pronounced: increased libido, spontaneous erections
Appetite Effects	Minimal	Significant appetite suppression via MC4R
Side Effects	Nausea, flushing, headaches	Nausea, yawning, flushing, sexual arousal, drowsiness
Clinical Development	Developed to Phase III; approved in some countries for erythropoietic protoporphyria (EPP) as Scenesse®	Development halted; not approved anywhere
Legal Status	Approved in EU, Australia, US for EPP (prescription only)	Not approved; illegal to sell for human use

Key Takeaway: Melanotan I is more selective and has a narrower, more predictable range of effects, which is why it advanced further in clinical development. Melanotan II's non-selectivity makes it more potent as a tanning agent but also more dangerous due to its widespread effects on multiple organ systems.

From Melanotan II to PT-141

The sexual side effects that derailed Melanotan II's development as a tanning agent became the foundation for a new drug.

When Palatin Technologies licensed Melanotan II from the University of Arizona, they initially pursued it for erectile dysfunction. Early trials showed promise, but severe nausea and a relatively long onset time limited its clinical value. Intranasal formulations were tested but also caused blood pressure concerns.

Palatin then synthesized bremelanotide (PT-141), a likely metabolite of Melanotan II. Bremelanotide differs from Melanotan II in that it has a hydroxyl group where Melanotan II has an amide. This small change altered the side effect profile.

After years of development, bremelanotide was reformulated for subcutaneous injection and tested in Phase III trials for female sexual dysfunction — specifically hypoactive sexual desire disorder (HSDD). The Reconnect trials demonstrated efficacy, and in 2019, the FDA approved bremelanotide under the brand name Vyleesi for premenopausal women with HSDD.

Bremelanotide is the only FDA-approved melanocortin receptor agonist for sexual dysfunction. Unlike illicit Melanotan II, it undergoes quality control, has defined dosing guidelines, and is used under medical supervision.

The story of Melanotan II and PT-141 illustrates an important principle: a compound with therapeutic potential may still require extensive modification, testing, and regulation before it's safe and appropriate for human use.

Frequently Asked Questions

Is Melanotan II legal? No. Melanotan II is not approved by the FDA, TGA, MHRA, or any major regulatory authority. Its sale for human use is illegal in the US, UK, Australia, and most other countries. It can only be legally sold to licensed researchers for non-human experimental purposes.

Can Melanotan II cause skin cancer? The link between Melanotan II and melanoma is not definitively established, but there are serious concerns. Case reports document melanoma in users, and the peptide causes darkening and proliferation of moles, including dysplastic (atypical) nevi. Stimulating melanocyte activity in predisposed individuals could theoretically accelerate melanoma development. Additionally, widespread mole darkening makes it harder to detect abnormal changes.

How does Melanotan II work? Melanotan II is a synthetic analog of α-MSH that binds to melanocortin receptors (MC1R, MC3R, MC4R, MC5R). Activation of MC1R in skin melanocytes stimulates melanin production, causing tanning. Activation of MC4R in the brain suppresses appetite and triggers sexual arousal. Because it's non-selective, Melanotan II affects multiple systems simultaneously.

What are the side effects of Melanotan II? Common side effects include nausea, flushing, yawning, stretching, fatigue, decreased appetite, and darkening of existing moles. Serious side effects documented in case reports include priapism, rhabdomyolysis, acute kidney injury, renal infarction, cardiovascular effects (elevated blood pressure and heart rate), and melanoma. Dysplastic nevi and other skin changes have also been reported.

Is Melanotan II the same as Melanotan I? No. Melanotan I (afamelanotide) is a linear 13-amino-acid peptide with greater selectivity for MC1R. It has fewer systemic side effects and is approved in some countries for erythropoietic protoporphyria (EPP) under the brand name Scenesse. Melanotan II is a shorter cyclic peptide with broader receptor activity and more side effects. Neither is approved for tanning.

What is the difference between Melanotan II and PT-141? PT-141 (bremelanotide) is a derivative of Melanotan II with a modified structure. It was developed by Palatin Technologies specifically for sexual dysfunction and received FDA approval in 2019 for hypoactive sexual desire disorder in women (brand name Vyleesi). While Melanotan II is illegal and unregulated, PT-141 is a prescription medication with defined dosing and safety monitoring.

Can I buy Melanotan II online? Yes, it's widely available from internet vendors, often labeled as "research peptides." However, purchasing and using it is illegal in most countries. Products sold online are unregulated, may be contaminated or mislabeled, and carry all the risks discussed in this article. There is no quality control, and you have no way to verify purity or dose accuracy.

Does Melanotan II require UV exposure? No. Melanotan II stimulates melanin production independently of UV radiation. However, many users combine it with sun or tanning bed exposure to accelerate or deepen tanning, which increases skin cancer risk further.

How long does Melanotan II stay in your system? Melanotan II has a longer half-life than natural α-MSH, but exact pharmacokinetics in humans are not well characterized in published literature. Effects can persist for hours to days after a single dose. The cyclic structure makes it more resistant to enzymatic breakdown than linear peptides.

The Bottom Line

Melanotan II is a potent, non-selective melanocortin receptor agonist that darkens skin but also triggers a cascade of effects throughout the body — some unpleasant, some dangerous. It was developed in the 1980s as a potential sunless tanning agent to reduce skin cancer risk, but its development was halted due to safety concerns. It has never been approved by any regulatory authority, and it remains illegal to sell for human use in most countries.

Despite this, Melanotan II circulates widely through unregulated internet vendors and gym networks. Users seeking a cosmetic tan are exposing themselves to documented risks: mole darkening and proliferation, potential melanoma, kidney damage (including rhabdomyolysis and renal infarction), cardiovascular effects, priapism, nausea, and other systemic side effects.

There is no medical oversight. No quality control. No way to verify dose, purity, or contamination. The products sold as "Melanotan II" online may not even contain what the label claims.

The theoretical appeal — a tan without UV exposure — is undermined by the reality that Melanotan II may increase cancer risk through different mechanisms: stimulating melanocyte proliferation in predisposed individuals, masking warning signs of melanoma through widespread mole darkening, and often being combined with UV exposure anyway.

For those interested in peptide science, the story of Melanotan II is instructive. It illustrates why regulatory approval processes exist, why selectivity matters in drug design, and how a compound with genuine biological activity can still be too dangerous for widespread use. The fact that a derivative — PT-141 (bremelanotide) — eventually received FDA approval for a different indication underscores that therapeutic potential must be paired with rigorous testing, quality control, and medical supervision.

If you're looking for safe ways to improve skin health or appearance, consult a dermatologist. If you're interested in peptides like BPC-157 or semaglutide that have more established research profiles, understand that even these compounds carry risks and require informed medical guidance.

Melanotan II is not a shortcut to a healthy tan. It's an unregulated, illegal compound with a documented record of serious adverse events. Health authorities worldwide — including the FDA, TGA, MHRA, and HPRA — explicitly warn against its use. That warning is backed by decades of research, clinical case reports, and the fact that its own developers abandoned it.

---

Disclaimer

This article is for informational and educational purposes only. It is not medical advice. Melanotan II is not approved for human use by the FDA or any other major regulatory authority. Its sale for human consumption is illegal in most countries. The information presented here is based on published scientific literature, case reports, and regulatory statements. PeptideJournal.org does not endorse, recommend, or encourage the use of Melanotan II or any other unapproved compound. Always consult a qualified healthcare provider before using any peptide or pharmaceutical agent.

---

References

1. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. PubMed

2. Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-9. PubMed

3. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012;50(10):1169-73. PubMed

4. Peters B, Hadimeri H, Mölne J, Nasic S, Jensen BL. Melanotan II: a possible cause of renal infarction: review of the literature and case report. BMC Nephrol. 2020;21(1):11. PMC Article

5. Cardones AR, Grichnik JM. Melanoma associated with the use of melanotan-II. Dermatology. 2014;229(3):190-2. PubMed

6. Machovcová A, Borská R, Arenberger P, Arenbergerová M. Eruptive dysplastic nevi following melanotan use. Actas Dermosifiliogr. 2012;103(7):648-50. Article

7. Langan EA, et al. Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. Dermatol Pract Concept. 2013;3(2):41-3. PMC Article

8. Brennan R, Wells JSG, Van Hout MC. An unhealthy glow? A review of melanotan use and associated clinical outcomes. Perform Enhanc Health. 2015;3(2):78-92. ScienceDirect

9. Hadley ME, Hruby VJ, Sawyer TK, et al. Discovery and development of novel melanogenic drugs: Melanotan-I and -II. In: Hormone Drugs. 1994. University of Arizona Research

10. Martin TJ, Ikeda Y. Bremelanotide for the treatment of hypoactive sexual desire disorder. Drugs Today (Barc). 2019;55(10):599-605.

11. U.S. Food and Drug Administration. Notice of Opportunity for Hearing (NOOH) Manookian, Edward 8/5/16. FDA

12. Therapeutic Goods Administration (Australia). Don't risk using tanning products containing melanotan. TGA Blog

13. Health Products Regulatory Authority (Ireland). Reminder of serious health risks with Melanotan 2 self-tan products. HPRA Notice

14. University of New South Wales. What is Melanotan-II - the drug that the TGA urges consumers to avoid? UNSW News

15. Greenfield JR, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-9.

16. Rinne P, Järvinen E, Savontaus E. Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice. Acta Physiol (Oxf). 2021;231(2):e13579. PubMed

17. van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A. 2002;99(17):11381-6.

18. Wikberg JE, Muceniece R, Mandrika I, et al. New aspects on the melanocortins and their receptors. Pharmacol Res. 2000;42(5):393-420.

19. Bertolini A, Poggioli R, Vergoni AV. Cross-species comparison of the MTII effects on sexual behavior and penile erection. Ann N Y Acad Sci. 2003;994:96-101.

20. Marks DL, Hruby V, Brookhart G, Cone RD. The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). Peptides. 2006;27(2):259-64.